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ABSTRACT
Autologous hematopoietic stem cell transplan-
tation (AHSCT) has been used in the treatment
of highly active multiple sclerosis (MS) for over
two decades. It has been demonstrated to be
highly efficacious in relapsing–remitting (RR)
MS patients failing to respond to disease-modi-
fying drugs (DMDs). AHSCT guarantees higher
rates of no evidence of disease activity (NEDA)
than those achieved with any other DMDs, but
it is also associated with greater short-term risks
which have limited its use. In the 2019 updated
EBMT and ASBMT guidelines, which review the
clinical evidence of AHSCT in MS, AHSCT
indication for highly active RRMS has changed
from ‘‘clinical option’’ to ‘‘standard of care’’. On
this basis, AHSCT must be proposed on equal
footing with second-line DMDs to patients with
highly active RRMS, instead of being considered
as a last resort after failure of all available
treatments. The decision-making process
requires a close collaboration between trans-
plant hematologists and neurologists and a full
discussion of risk–benefit of AHSCT and alter-
native treatments. In this context, we propose a
standardized protocol for decision-making and
informed consent process.
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Some patients with multiple sclerosis (MS)
still experience disease activity despite
treatment with highly efficacious disease-
modifying drugs (DMDs).
Autologous hematopoietic stem cell
transplantation (AHSCT) guarantees
higher rates of no evidence of disease
activity (NEDA) than those achieved with
any other DMDs, but it is also associated
to greater short-term risks which have
limited its use.
The 2019 updated EBMT and ASBMT
guidelines change the AHSCT indication
for highly active RRMS from ‘‘clinical
option’’ to ‘‘standard of care’’; thus AHSCT
should be proposed to these patients on
equal footing with second-line DMDs.
Here we propose a standardized protocol
for a decision-making and informed
consent process implemented at our
center.
Multiple sclerosis (MS) is a heterogeneous
inflammatory disease affecting the central ner-
vous system (CNS), in which a deep immuno-
logical alteration gives rise to pathologic
phenomena leading to the progressive and
irreversible degeneration of the CNS [1].
Significant therapeutic advances have been
made in recent decades, and more than a dozen
disease-modifying drugs (DMDs) have been
approved for treatment of relapsing–remitting
(RR) MS. Based on the approval of authorities
such as the European Medicines Agency (EMA),
DMDs are usually differentiated into first-line
drugs (interferon beta-1b, interferon beta-1a -sc,
im-, peginterferon beta-1a, glatiramer acetate,
teriflunomide, dimethyl fumarate) and second-
line drugs (cladribine, fingolimod, natalizumab,
ocrelizumab and alemtuzumab), which differ in
their effectiveness, safety profile and route of
administration [2]. The second-line treatments
are recommended for patients with an active
course of MS who failed to respond to the first
line. The European Committee for Treatment
and Research in Multiple Sclerosis (ECTRIMS),
the European Academy of Neurology (EAN) and
the American Academy of Neurology (AAN)
have developed guidelines to support neurolo-
gists in the pharmacological treatment of
patients affected by MS and to enable homo-
geneity of treatment decisions across countries
[3, 4].
The majority of DMDs are administered
repeatedly with a long-term maintenance
approach, which has implications in terms of
patient compliance, risk of complications and
health cost [5]. DMD costs account for most of
the direct healthcare costs in MS. They have
rapidly risen in the past few years and are
expected to further increase among overall
expenses, to the point where some studies esti-
mate them to be beyond the health care system
tolerance or the generally accepted cost-effec-
tiveness thresholds [6, 7]. Some DMDs have
been proven highly efficacious, at the expense
of potential life-threatening side effects, e.g.
progressive multifocal leukoencephalopathy
(PML) for natalizumab, the important lym-
phopenia for cladribine, ocular disorders for
fingolimod, and the increased risk of pul-
monary hemorrhages, heart attacks, strokes and
cervical-cephalic arterial dissection for alem-
tuzumab [2, 7]. DMD treatment reduces the
number of relapses and progression of disability
in the short term, and an emerging corpus of
data suggests that the onset of a secondary
progressive phase can also be delayed [8, 9].
However, some patients still have ongoing dis-
ease activity despite treatment with newer,
highly efficacious DMDs, with no evidence of
disease activity (NEDA) rates lower than 50% at
2 years [10, 11].
Ablation of the immune system followed by
autologous hematopoietic stem cell transplan-
tation (AHSCT) for the treatment of MS has
been explored for approximately two decades
since the original pivotal report of its feasibility
[12]. AHSCT is a once-only treatment whose
therapeutic effect could last for many years;
thus it might represent a cost-saving opportu-
nity compared with continuous treatment with
DMDs [7, 13].
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The European Group for Blood and Marrow
Transplantation (EBMT) Autoimmune Disease
Working Party (ADWP) and the American
Society for Blood and Marrow Transplantation
(ASBMT) gather scientists, neurologists and
hematologists, with the goal of registering
HSCT activity and promoting multicenter ret-
rospective studies and randomized controlled
trials. To date, several registry studies and two
prospective comparative trials have provided
evidence that AHSCT is highly effective in
suppressing inflammatory MS activity [14–17].
Two meta-analyses of studies on patients
undergoing transplants since 1995 have agreed
that AHSCT can induce long-term remission for
RRMS patients [17, 18]. The main concern lim-
iting the use of AHSCT is the mortality risk.
However, treatment-related mortality (TRM),
which was initially high (3.6%), has decreased
to 0.3% in studies post-2005, thanks to the
greater experience and the accreditation of
centers, improvements in transplant techniques
and optimization of patient selection [18].
Major complications of AHSCT are secondary to
the immunosuppression, and include febrile
neutropenia, sepsis, urinary infections and viral
reactivations. Late adverse events have also
been described, including infertility, malignan-
cies and secondary autoimmune conditions.
However, menstruation recovery and good
pregnancy outcome have been described in
women after AHSCT for autoimmune diseases
[19, 20]. Also, long-term follow-up studies
report an incidence of secondary malignancies
comparable to other DMDs, and a rate of sec-
ondary autoimmune conditions significantly
lower than some DMDs, such as alemtuzumab
[16]. No cases of PML have been reported so far
in the literature, including patients with high
titers of John Cunningham virus (JCV) anti-
bodies previously treated with natalizumab. On
the other hand, NEDA rates 2 years after AHSCT
exceed 70%, which is considerably higher than
DMDs. This suggests that AHSCT has a more
extensive effect on disease activity, especially
considering that participants in AHSCT trials
usually experience more aggressive disease than
the participants in all the other clinical trials
[10, 11]. Patients with the RR form, a low level
of disability, and clinical and MRI signs of
disease activity show the best benefit/risk ratio
from AHSCT [11, 18].
Multidisciplinary guidelines have been pub-
lished over the years to advise on the selection
and management of patients based on clinical
evidence and registry activity [21–25]. Since
2012, with the publication of the EBMT-ADWP
guidelines defining AHSCT as a clinical option
in RRMS [22], MS has appeared as the fastest-
growing indication for AHSCT among autoim-
mune diseases. Given the rapidly accumulating
evidence on the health benefits and risks bal-
anced against the non-AHSCT options, in the
most recent updated EBMT-ADWP and ASBMT
guidelines, the indication for AHSCT has been
revised [24, 25]. AHSCT is now recommended as
a standard of care for highly active RRMS failing
at least one line of DMD, as defined by the
occurrence of two clinical relapses or a clinical
relapse and MRI activity at different time points
within the prior 12 months. For patients with
aggressive RRMS who developed severe disabil-
ity in the previous 12 months, AHSCT is con-
sidered a clinical option before failing a full
course of DMD.
For years, AHSCT has been considered as a
last resort after failure of all available treat-
ments. Based on new EBMT and ASBMT guide-
lines, AHSCT should be proposed on equal
footing with second-line DMDs to patients with
highly active RRMS, particularly young patients
with short disease duration and low Expanded
Disability Status Scale (EDSS) score. However,
several aspects deserve particular attention [24].
The setting of the AHSCT delivery should be
transplant units accredited by JACIE [Joint
Accreditation Committee ISCT-Europe] or
equivalent and with close collaboration
between neurologists and hematologists. Inter-
mediate-intensity conditioning regimens are
recommended. The informed consent process
should include a full discussion of risk–benefit
of AHSCT and alternative treatments with both
neurologists and hematologists.
In this context, we have implemented a
standardized protocol for the multidisciplinary
decision-making and informed consent process
for treatment of RRMS patients failing a second-
line DMD. Step by step procedure is summa-
rized in Fig. 1. This protocol gives patients the
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Fig. 1 Standardized protocol implemented at CRESM and SSD Terapia oncoematologica intensiva e trapianto CSE for the
multidisciplinary decision-making and informed consent process for treatment of RRMS patients failing a second-line
DMD
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chance to choose a one-shot alternative treat-
ment showing high rates of efficacy as against
severe but rare short-term risks, which is in line
with ECTRIMS/EAN guidelines recommending
clinicians to engage patients in an ongoing
dialogue regarding treatment decisions coun-
tries [3, 4].
To date, economic evaluations and cost-ef-
fectiveness analyses comparing AHSCT and
different DMDs are lacking. However, based on
our experience, we made an attempt to estimate
the impact of AHSCT on the pharmaceutical
cost burden to the Italian health care system.
Since 2001, 11 RRMS patients have undergone
AHSCT with intermediate-intensity condition-
ing regimens at our center, with a NEDA rate of
91% (median (range) follow-up: 58 months
(6–224)). Considering a mean cost of €18,000
per year for therapy with DMDs, and a one-off
cost of €38,000 for the AHSCT, the estimated
savings amount to €611,000. This corresponds
to 57% of the pharmaceutical spending expec-
ted for continuous treatment with DMDs for all
patients throughout the same follow-up period.
The cost savings would be much higher when
considering that management costs for trans-
planted patients are low, and patients are likely
to experience good quality of life in the long
term. Although comparative clinical studies and
health economic evaluations are necessary to
lead decision-making, the evidence of a favor-
able cost-effectiveness ratio supports an increase
in AHSCT delivery in the future.
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